Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 8/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NQO1 | P15559 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5043671 | 0.89 | ACACB (0.50) | ACACBNPC1RAB9AMAPTMEN1 | |
| SCHEMBL5043437 | 0.86 | ACACB (0.51) | ACACBNPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL5048237 | 0.85 | ACACB (0.49) | ACACBRAB9AMAPTMEN1KMT2A | |
| SCHEMBL5043428 | 0.85 | ACACB (0.49) | ACACBNPC1RAB9AMAPTHTT | |
| SCHEMBL5046828 | 0.84 | ACACB (0.48) | ACACB | |
| SCHEMBL5043418 | 0.83 | ACACB (0.47) | ACACBMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL5046813 | 0.83 | ACACB (0.55) | ACACBNPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL5046911 | 0.81 | ACACB (0.53) | ACACBALDH1A1 | |
| SCHEMBL5046536 | 0.80 | ACACB (0.54) | ACACBNPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL5046845 | 0.80 | ACACB (0.56) | ACACBNPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459480-B2 | Benzodioxepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-12-02 | — | — | US | claimed |
| EP-1682528-B1 | BENZO [b][1,4] DIOXEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2007-09-12 | — | — | EP | claimed |
| US-20050113374-A1 | Benzodioxepine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-26 | — | — | US | claimed |
| US-7459480-B2 | Benzodioxepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-12-02 | — | — | US | disclosed |
| EP-1682528-B1 | BENZO [b][1,4] DIOXEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2007-09-12 | — | — | EP | disclosed |
| US-20050113374-A1 | Benzodioxepine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113374-A1 | Benzodioxepine derivatives | BBOX1, ACOX1, ACOX3 | ACACB 5/4885NPC1 2203/4885RAB9A 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.